Quantum Biopharma (QNTM) Receivables (2018 - 2026)
Quantum Biopharma (QNTM) posted Receivables of $417048.0 for Q1 2026, down 9.75% sequentially from $462106.0 in Q4 2025, and down 47.05% YoY from $787686.0 in Q1 2025.
Quantum Biopharma (QNTM) Receivables (2018 - 2026) Analysis & Trends
Quantum Biopharma has reported Receivables for 9 years, with the latest figure at $417048.0 in Q1 2026.
- Quarterly Receivables fell 47.05% year-over-year to $417048.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $417048.0 (down 47.05% YoY) and the FY2025 annual result came in at $462106.0, down 38.33% from the prior year.
- Receivables retreated to $417048.0 in Q1 2026 per QNTM's latest filing, from $462106.0 in the prior quarter.
- Over five years, Receivables peaked at $787686.0 in Q1 2025 and troughed at $156600.0 in Q3 2025.
- A 5-year average of $432255.7 and a median of $401722.0 in 2025 frame the typical range for Receivables.
- The sharpest annual moves came in 2023 and 2024: Receivables sank 68.95% in 2023, then jumped 222.35% in 2024.
- Over 5 years, Receivables stood at $748754.0 in 2022, then tumbled by 68.95% to $232467.0 in 2023, then surged by 222.35% to $749356.0 in 2024, then slumped by 38.33% to $462106.0 in 2025, then retreated by 9.75% to $417048.0 in 2026.
- According to Business Quant data, Receivables over the past three periods registered $417048.0, $462106.0, and $156600.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Quantum Biopharma | 15.53 Mn | 11.89 Mn | - | 215,268.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 215,268.00 |
| Mar 31, 2026 | 417,048.00 |
| Dec 31, 2025 | 462,106.00 |
| Sep 30, 2025 | 156,600.00 |
| Jun 30, 2025 | 386,396.00 |
| Mar 31, 2025 | 787,686.00 |
| Dec 31, 2024 | 749,356.00 |
| Sep 30, 2024 | 208,408.00 |
| Jun 30, 2024 | 173,736.00 |
| Dec 31, 2023 | 232,467.00 |
| Dec 31, 2022 | 748,754.00 |
| Dec 31, 2021 | 500,964.00 |
| Sep 30, 2021 | 396,353.00 |
| Jun 30, 2021 | 130,709.00 |
| Mar 31, 2021 | 184,182.00 |
| Dec 31, 2020 | 187,967.00 |
| Jun 30, 2020 | 1.98 Mn |
| Mar 31, 2020 | 1.45 Mn |
| Dec 31, 2019 | 3.14 Mn |
| Jun 30, 2019 | -244,437.62 |